RECEIVED CENTRAL FAX CENTER

JAN 0 3 2008 try Docket No. 019026-000110US

PTO FAX NO.: 1-571-273-8300

ATTENTION:

Examiner R. P. Swartz

Group Art Unit 1645

OFFICIAL COMMUNICATION FOR THE PERSONAL ATTENTION OF

EXAMINER R. P. Swartz

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents in re Application of YOH-ICHI MATSUMOTO et al., Application No. 09/700,851, filed November 17, 2000 for HUMANIZED ANTIBODIES THAT RECOGNIZE VEROTOXIN II AND CELL LINE PRODUCING SAME are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Response to Advisory Action Before the Filing of an Appeal Brief

Number of pages being transmitted, including this page: 10

Dated: 1/3/2008

Tamara Tucker

PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FACSIMILE AT (415) 576-0300

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, CA 94111-3834 Telephone: 650-326-2400

Fax: 650-326-2422

0229

61246961 v1

RECEIVED CENTRAL FAX CENTER

JAN 0 3 2008

Attorney Docket No.: 019026-000110US

Client Ref. No.: T-400

Thereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-571-273-8300 on January 3, 2008.

TOWNSEND and TOWNSEND and CREW LLP

3y: <u>□ γα.</u> Tamara Tucker

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

YOH-ICHI MATSUMOTO et al.

Application No.: 09/700,851

Filed: November 17, 2000

For: HUMANIZED ANTIBODIES THAT RECOGNIZE VEROTOXIN II AND CELL LINE PRODUCING SAME

Customer No.: 20350

Mail Stop AF
Commissioner for Patents
P.O. Box 1450

Alexandria, VA 22313-1450

Confirmation No. 3540

Examiner:

R. P. Swartz

Technology Center/Art Unit: 1645

RESPONSE TO ADVISORY ACTION BEFORE THE FILING OF AN APPEAL

BRIEF

Sir:

In response to the Advisory Action Before the Filing of an Appeal Brief mailed on December 21, 2007, for the above-referenced application, please enter the following amendments and remarks:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks begin on page 8 of this paper.